Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?

被引：44

作者：

Andre, Fabrice ^{[1
]}

Delaloge, Suzette ^{[1
]}

Soria, Jean-Charles ^{[1
]}

机构：

[1] Inst Gustave Roussy, INSERM, U981, F-94805 Villejuif, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 10期

关键词：

CELL LUNG-CANCER; BREAST-CANCER; TRASTUZUMAB; EML4-ALK; PATHWAY; GENE;

D O I：

10.1200/JCO.2010.31.6877

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1236 / 1238

页数：3

共 15 条

[1] Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array [J].

Andre, Fabrice ;

Job, Bastien ;

Dessen, Philippe ;

Tordai, Attila ;

Michiels, Stefan ;

Liedtke, Cornelia ;

Richon, Catherine ;

Yan, Kai ;

Wang, Bailang ;

Vassal, Gilles ;

Delaloge, Suzette ;

Hortobagyi, Gabriel N. ;

Symmans, W. Fraser ;

Lazar, Vladimir ;

Pusztai, Lajos .

CLINICAL CANCER RESEARCH, 2009, 15 (02) :441-451

[2] A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer [J].

Berns, Katrien ;

Horlings, Hugo M. ;

Hennessy, Bryan T. ;

Madiredjo, Mandy ;

Hijmans, E. Marielle ;

Beelen, Karin ;

Linn, Sabine C. ;

Gonzalez-Angulo, Ana Maria ;

Stemke-Hale, Katherine ;

Hauptmann, Michael ;

Beijersbergen, Roderick L. ;

Mills, Gordon B. ;

de Vijver, Marc J. van ;

Bernards, Rene .

CANCER CELL, 2007, 12 (04) :395-402

[3] Oncogenic pathway signatures in human cancers as a guide to targeted therapies [J].

Bild, AH ;

Yao, G ;

Chang, JT ;

Wang, QL ;

Potti, A ;

Chasse, D ;

Joshi, MB ;

Harpole, D ;

Lancaster, JM ;

Berchuck, A ;

Olson, JA ;

Marks, JR ;

Dressman, HK ;

West, M ;

Nevins, JR .

NATURE, 2006, 439 (7074) :353-357

[4]

*CLINICALTRIALS GO, STAND NEOADJ CHEM VE

[5]

*CLINICALTRIALS GO, RAND CLIN TRIAL EV P

[6] Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression pro-filing study [J].

Gong, Yun ;

Yan, Kai ;

Lin, Feng ;

Anderson, Keith ;

Sotiriou, Christos ;

Andre, Fabrice ;

Holmes, Frankie A. ;

Valero, Vicente ;

Booser, Daniel ;

Pippen, John E., Jr. ;

Vukelja, Svetislava ;

Gomez, Henry ;

Mejia, Jaime ;

Barajas, Luis J. ;

Hess, Kenneth R. ;

Sneige, Nour ;

Hortobagyi, Gabriel N. ;

Pusztai, Lajos ;

Symmans, W. Fraser .

LANCET ONCOLOGY, 2007, 8 (03) :203-211

[7] KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer [J].

Lièvre, A ;

Bachet, JB ;

Le Corre, D ;

Boige, V ;

Landi, B ;

Emile, JF ;

Côté, JF ;

Tomasic, G ;

Penna, C ;

Ducreux, M ;

Rougier, P ;

Penault-Llorca, F ;

Laurent-Puig, P .

CANCER RESEARCH, 2006, 66 (08) :3992-3995

[8] Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples [J].

MacConaill, Laura E. ;

Campbell, Catarina D. ;

Kehoe, Sarah M. ;

Bass, Adam J. ;

Hatton, Charles ;

Niu, Lili ;

Davis, Matt ;

Yao, Keluo ;

Hanna, Megan ;

Mondal, Chandrani ;

Luongo, Lauren ;

Emery, Caroline M. ;

Baker, Alissa C. ;

Philips, Juliet ;

Goff, Deborah J. ;

Fiorentino, Michelangelo ;

Rubin, Mark A. ;

Polyak, Kornelia ;

Chan, Jennifer ;

Wang, Yuexiang ;

Fletcher, Jonathan A. ;

Santagata, Sandro ;

Corso, Gianni ;

Roviello, Franco ;

Shivdasani, Ramesh ;

Kieran, Mark W. ;

Ligon, Keith L. ;

Stiles, Charles D. ;

Hahn, William C. ;

Meyerson, Matthew L. ;

Garraway, Levi A. .

PLOS ONE, 2009, 4 (11)

[9] Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. [J].

Mok, Tony S. ;

Wu, Yi-Long ;

Thongprasert, Sumitra ;

Yang, Chih-Hsin ;

Chu, Da-Tong ;

Saijo, Nagahiro ;

Sunpaweravong, Patrapim ;

Han, Baohui ;

Margono, Benjamin ;

Ichinose, Yukito ;

Nishiwaki, Yutaka ;

Ohe, Yuichiro ;

Yang, Jin-Ji ;

Chewaskulyong, Busyamas ;

Jiang, Haiyi ;

Duffield, Emma L. ;

Watkins, Claire L. ;

Armour, Alison A. ;

Fukuoka, Masahiro .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) :947-957

[10] Next-generation sequencing [J].

Reis-Filho, Jorge S. .

BREAST CANCER RESEARCH, 2009, 11

← 1 2 →